Company developing simple and direct interventions targeting toxic forms of cholesterol for age-related diseases.
Underdog Pharmaceuticals, Inc., is pursuing a mission to treat the underlying causes of age-related disease. The company develops simple and direct interventions targeting toxic forms of cholesterol, using rationally designed molecules, to provide the first true disease-modifying treatments for age-related diseases such as atherosclerosis, hypercholesterolemia, heart failure, and macular degeneration.
Underdog was built from an SRF flagship program that has driven two years of applied development designed to explore and repair the underlying causes of cardiovascular disease. Its co-founders are Matthew O’Connor, Ph.D., and Michael Kope, formerly the Vice President of Research and the founding Chief Executive Officer, respectively, of SRF.
Visit website: https://underdogpharma.com/
See also: SENS Research Foundation - Non-profit organization focused on transforming the way the world researches and treats age-related diseases
People at Underdog Pharmaceuticals
Co-Chief Executive Officer and Co-founder Underdog Pharmaceuticals
Co-Chief Executive Officer and Co-founder of Underdog Pharmaceuticals.
Underdog Pharmaceuticals News
Underdog pharmaceuticals secures $10m funding from Kizoo ventures
Longevity Technology - 23-Sep-2021
Funds to bring affordable and effective age-related therapies to the publicRead more...
'Innovation Passport' awarded for Underdog's novel compound intended for treating heart diseases
Longevity Technology - 09-Sep-2021
Safe and potential compound shows disease-modifying effect by removing toxic cholesterol from bloodRead more...
Two drug molecules delivered via nanoparticles to combat atherosclerosis
Lifespan.io (LEAF) - 26-Jun-2020
Success in mice model gives hope for fighting cholesterol-associated inflammatory diseasesRead more...
Fight Aging! reports back from SENS Research Foundation Pitch Day
Fight Aging! - 20-Jan-2020
When some of these succeed in human trials even more money will pile in to fund further advancesRead more...